$NTRA

Generating a unique summary for NTRA…

AI-generated for information only — not investment advice.

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Institutions hold 96.79% · insiders 2.85% · 1,183 institutions

Consensus score 1.50 (1 = strong buy, 5 = sell) · mean target 338.07

• CitigroupBuymain2026-08-13
• Piper SandlerOverweightmain2026-08-12
• Stephens & Co.Overweightmain2026-08-12
• GuggenheimBuymain2026-08-12
• TD CowenBuymain2026-08-07
• CitigroupBuymain2026-08-07
• RBC CapitalOutperformmain2026-08-07
• JP MorganOverweightmain2026-08-07
• Wells FargoEqual-Weightmain2026-08-07
• Evercore ISI GroupOutperformmain2026-08-07

Next report: 2026-11-05

• 10-QPeriodic Financial Reports2026-08-07Open
• 8-KCorporate Changes & Voting Matters2026-08-06Open
• 8-KCorporate Changes & Voting Matters2026-07-06Open
• 8-K/ACorporate Changes & Voting Matters2026-06-16Open
• 8-KCorporate Changes & Voting Matters2026-06-05Open
• 10-QPeriodic Financial Reports2026-05-08Open
• 8-KCorporate Changes & Voting Matters2026-05-07Open
• DEF 14AProxy Statements2026-04-23Open
• 8-KCorporate Changes & Voting Matters2026-04-01Open
• S-8Offering Registrations2026-03-02Open

• New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma

  AUSTIN, Texas, September 01, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in patients with both newly diagnosed and relapsed/refractory (R/R) lymphoma.

  Tue, 01 Sep 2026 10:00:00 +0000

• Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run?

  The billionaire has good reasons to like this genetic testing leader.

  Sat, 29 Aug 2026 10:12:00 +0000

• Natera & Angiex Partner to Evaluate AGX101 Response With Signatera

  NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.

  Fri, 28 Aug 2026 15:22:00 +0000

• Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer

  AUSTIN, Texas, August 28, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a national partnership with Susan G. Komen®, the world’s leading breast cancer organization. Together, the organizations aim to accelerate breast cancer awareness and education, including efforts to increase understanding of MRD. Natera’s SignateraTM MRD test is supported by more than 185 peer-reviewed publications across multiple cancer types, including b

  Fri, 28 Aug 2026 15:03:00 +0000

• 3 Healthcare Stocks with Promising Prospects

  Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 24.9% gain over the past six months, beating the S&P 500 by 13.3 percentage points.

  Thu, 27 Aug 2026 15:37:07 +0000

• Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™

  AUSTIN, Texas, August 27, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new Signatera collaboration with Angiex, Inc., a privately held biotech company developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs).

  Thu, 27 Aug 2026 10:00:00 +0000

• Natera (NTRA) Supplies MRD Assay For Phase 1 Skin Cancer Immunotherapy Trial

  Natera (NasdaqGS:NTRA) announced a collaboration with Kupando Therapeutics to supply its Latitude tissue-free MRD assay for a Phase 1 immunotherapy trial in multiple skin cancers. The Latitude assay will be used to monitor minimal residual disease and treatment response in patients receiving Kupando's investigational therapy. The partnership expands Natera's presence in oncology clinical trials and supports use of its MRD technology across different tumor types. This kind of cancer trial...

  Wed, 26 Aug 2026 18:20:22 +0000

• Q2 Rundown: Natera (NASDAQ:NTRA) Vs Other Biotechnology Stocks

  The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks fared in Q2, starting with Natera (NASDAQ:NTRA).

  Tue, 18 Aug 2026 18:05:33 +0000